The Kiteworks research reveals that 27% of life organizations acknowledge that more than 30% of their AI-processed data ...

To navigate the complexities of sophisticated drug development and manufacturing, a fundamental shift toward AI-powered ...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you ...

OPRX raised guidance after record Q1 EBITDA, but pharma budget shifts and margin mix pose new challenges ahead.

Regeneron Pharma Inc. (REGN) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. Today, at ...

Tariffs and Middle East turmoil are spooking European companies and the investors weighing their initial public offerings ...

Incyte shares rose Thursday after the drugmaker named Bill Meury its new CEO, effective immediately, to replace the retiring ...

Fintel reports that on June 17, 2025, Wolfe Research initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Outperform recommendation. Analyst Price Forecast Suggests 49.69% Upside As of June 2 ...

In STEMI-induced cardiogenic shock, a microaxial flow pump can unload the heart by reducing native cardiac output and ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’ Substack by Kontra. In this ...

Doximity scores very highly on the Rule of 40, reaching 58%. Click here to find out why I rate DOCS stock a Strong Buy.